Find Funding Opportunities

This Funding Opportunity Announcement (FOA) seeks applications for the Data Innovation and Coordinating Hub/Resource Center (hereafter referred to as the Innovation and Data Hub) for the Maternal Health Research Centers of Excellence initiative. This FOA runs in parallel with companion FOAs that seek applications for Research Centers of Excellence (RFA-HD-23-NNN) and an Implementation Science Hub/Resource Center (RFA-HD-23-NNN). It is expected that the Innovation and Data Hub will provide 1) a coordination infrastructure to foster communication and collaboration for participating Research Centers and the Implementation Science Hub under the Maternal Health Centers of Excellence initiative, 2) a centralized resource to support data collection, facilitate curation, and ensure high-quality data, and 3) provide cutting edge biomedical research informatics and data science expertise to maximize data comparability and facilitate data harmonization. The Innovation and Data Hub itself will not generate new experimental data, but rather will serve as a resource, analytical platform, and portal for available analytical and data tools.

The purpose of this Funding Opportunity Announcement (FOA) is to support studies that expand the use of existing AD/ADRD data resources to drive new discoveries that can lead to better understanding of the relationship between early life social determinants of health (SDOH), adverse childhood experiences (ACEs), AD/ADRD biomarkers, and the development of cognitive impairment and dementia, especially in populations experiencing health disparities.

This funding opportunity announcement (FOA) invites research to develop, characterize, and rigorously validate non-rodent mammalian models of pain, associated outcome measures and/or endpoints that enable translational research for effective pain management. These models are expected to recapitulate molecular, cellular, pathological, behavioral, and/or cognitive aspects of human pain disorders and conditions. Research supported under this FOA is expected to provide well-validated models and measures that facilitate the development of non-opioid analgesic therapeutic interventions with little or no addiction liability.

The purpose of this NINDS-led Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) initiative is to 1) develop tools, standards, and an Open-source software platform that enables a federated (multiple data repository sites with a single access portal) approach for data sharing and analysis of human digital neuropathological slides and 2) perform software testing to validate and verify that the software and tools developed can be used to perform multisite neuropathological analyses using a federated approach. The federated approach requires a single access point of digital slides from multiple geographically distinct brain banks. The resources developed are expected to also enable cross-site annotation and computational image analysis, including advanced analytic approaches. A critical feature of this FOA includes the broad sharing of neuropathological data to further advance research in this area, including the development of a digital resource for distribution and sharing of assessed neuropathological tissue. Software and tools developed under this initiative are expected to be shared using Open Science principles, and the federated digital library is expected to follow FAIR data sharing principles.

This funding opportunity announcement (FOA) encourages early-stage development of novel small molecule or biologic therapeutics for NINDS mission-relevant? Alzheimer's and related dementias: frontotemporal degeneration (FTD, including Picks disease and progressive supranuclear palsy), Lewy body dementias (LBD; including dementia with Lewy bodies (DLB) and Parkinsons disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED). This FOA covers four stages of early therapy discovery/development with each stage gated by go/no-go milestones. Applicants may enter the program at the stage appropriate to their research. The R61 phase supports preparatory research stages 1 -3: 1) development of in vitro and/or ex vivo assays that can support therapeutic screening efforts, 2) screening efforts to identify and characterize potential therapeutic agents, and 3) therapeutic optimization, pharmacodynamic and pharmacokinetic studies. The R33 phase supports stage 4, in vivo efficacy studies in an animal model of disease. This FOA supports research to enable competitive follow-on applications that meet the entry criteria for the Blueprint Neurotherapeutics Network, Blueprint Biologics, or other similar later-stage translational programs.

The accumulation of misfolded proteins in the brain is a key pathological feature shared by many neurodegenerative diseases that can result in dementia such as Alzheimers Disease, Lewy Body Diseases, Frontotemporal Degeneration, and cerebral amyloid angiopathy. Classical prion diseases such as Creutzfeldt-Jakob Disease are a rare family of neurodegenerative disorders that occur when the cellular prion protein (PrPC) undergoes structural conversion to a pathological form (PrPSc), which is usually triggered by its interaction with an infectious variant of the protein that forces the conformational change. Once this process is initiated, it becomes self-propagating until toxic aggregates accumulate within the CNS, leading to neuronal death. Because misfolded proteins of AD/ADRD have been reported to share some features with pathological prion protein at the structural level, it has thus been proposed that ADRD-relevant proteins such as Alpha, tau, beta-synuclein, and TDP-43 (among others) may exhibit prion-like behaviors that lead to toxic aggregate and tangle formation. The goal of this initiative is to promote studies that increase our understanding of the cellular and molecular mechanisms by which such prion-like conversion events occur and are propagated in AD/ADRD, as well as the downstream mechanisms that trigger neurotoxicity, pathological and circuit changes in the brain.

The purpose of this Limited Competition Funding Opportunity Announcement is to allow Undiagnosed Diseases Network (UDN) Clinical Sites that received an NIH award under RFA-RM-17-019 an opportunity to compete for one additional year of NIH funding to: continue their participation in the UDN; establish collaborations and efficient processes with the next phase Data Management and Coordinating Center (DMCC; see: RFA-NS-22-051); enroll and evaluate new participants; and further develop their sustainability plans.

The goal of this effort is to support the development and validation of next generation platforms and analytic approaches to precisely quantify behaviors in humans and link them with simultaneously recorded brain activity. Tools used for analyzing behavior should be multi-modal and should be able to be linked to brain activity and thus have the accuracy, specificity, temporal resolution, and flexibility commensurate with tools used to measure and modulate the brain circuits that give rise to those behaviors. This phased award will support novel tool development (i.e., hardware/software) in the R61 phase and synchronization of novel tools for measuring behavior and human brain activity in the R33 phase.

The purpose of this FOA is to solicit applications for a Coordinating Center to provide leadership for the HEAL Coordinated Approaches to Pain Care in Health Care Systems Program. The Coordinating Center will 1) work collaboratively with each Project team supported through the Collaboratory program, including their partnering health care system (HCS), to develop, test, and implement the proposed Projects while providing technical, design, and coordination support; 2) provide centralized resources (e.g., electronic health records expertise, study design and statistical expertise for implementation trials, bioethics and regulatory expertise) for coordination and integration of the research effort across all projects; and 3) centralize the engagement of patients, care providers, health care systems, payors, and policy makers to inform the activities of the program of research, with a particular focus on HCS with less historical involvement in research studies. The Coordinating Center also will serve as the central administrative resource for the activities of the Coordinated Approaches to Pain Care Program.

Emergency Award: This Funding Opportunity Announcement (FOA) solicits research applications that propose implementation science methodology to embed existing evidence-based coordinated pain care models into a variety of public and private health care systems (HCS) where this type of care does not exist. Applications that combine comparative effectiveness studies of innovative coordinated care models with strong implementation science methodology to embed effective approaches into HCSs also are encouraged. This FOA requires that the coordinated care model under study be embedded into the health care delivery system of the applicant institutions. Coordinated pain care approaches proposed for study should include interventions from multiple disciplines as described below and should aim to improve pain management based on the biopsychosocial model of pain. Emphasis should be on populations of patients with greatest need. This FOA solicits applications from HCS who have resources and infrastructure to support research and implementation of study approaches in partnership with those HCS who lack research resources or experience and would benefit most from implementation of cost-effective coordinated pain care. HCS partners who serve populations that are under-represented in research are encouraged to apply. Models of coordinated care proposed by the study team should be aligned with health care resources of the participating HCS and should be informed through engagement of stakeholders including patients, providers, healthcare system executives, policy makers, and payors. The study teams must include health care providers from multiple disciplines and implementation scientists.